Patrizia Comoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/461388/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies. Cytotherapy, 2022, 24, 544-556.	0.7	7
2	Successful JC virus-targeted T-cell therapy for progressive multifocal leukoencephalopathy in a lung transplant recipient. Journal of Heart and Lung Transplantation, 2022, 41, 991-996.	0.6	1
3	Developing cell therapies as drug products. British Journal of Pharmacology, 2021, 178, 262-279.	5.4	6
4	Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies. International Journal of Molecular Sciences, 2021, 22, 1906.	4.1	19
5	Adoptive Transfer of <scp>JC</scp> Virusâ€Specific T Lymphocytes for the Treatment of Progressive Multifocal Leukoencephalopathy. Annals of Neurology, 2021, 89, 769-779.	5.3	30
6	Post-transplant de novo non donor-specific HLA antibodies are not associated with poor graft outcome in non-sensitized pediatric recipients of kidney transplantation. Transplant Immunology, 2021, 65, 101375.	1.2	1
7	Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2021, 22, 9159.	4.1	7
8	Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges. Cancers, 2021, 13, 4582.	3.7	28
9	Management of PTLD After HSCT. , 2021, , 221-237.		Ο
10	Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives. Frontiers in Immunology, 2020, 11, 567020.	4.8	16
11	NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?. International Journal of Molecular Sciences, 2020, 21, 8975.	4.1	26
12	Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2020, 11, 567531.	4.8	10
13	Air pollution as a contributor to the inflammatory activity of multiple sclerosis. Journal of Neuroinflammation, 2020, 17, 334.	7.2	28
14	Progressive multifocal leukoencephalopathy responsive to withdrawal of imatinib in a patient with FIP1L1-PDGFRA positive myeloid neoplasm. Leukemia and Lymphoma, 2020, 61, 2226-2229.	1.3	1
15	Failure to removede novodonor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study. Transplant International, 2019, 32, 38-48.	1.6	11
16	Development of adaptive immune effector therapies in solid tumors. Annals of Oncology, 2019, 30, 1740-1750.	1.2	35
17	Growth Impairment in Acute Central Infectious Diseases. Journal of Pediatric Infectious Diseases, 2019, 14, 011-012.	0.2	0
18	Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. Oncotarget, 2019, 10, 869-882.	1.8	25

#	Article	IF	CITATIONS
19	Circulating B Cells With Memory and Antibody-Secreting Phenotypes Are Detectable in Pediatric Kidney Transplant Recipients Before the Development of Antibody-Mediated Rejection. Transplantation Direct, 2019, 5, e481.	1.6	6
20	Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study. Leukemia and Lymphoma, 2018, 59, 225-228.	1.3	3
21	Long lasting responses to adoptive T-cell therapy in relapsed EBV-related nasopharyngeal carcinoma. Annals of Oncology, 2018, 29, viii378.	1.2	0
22	Minimal/Measurable Residual Disease Monitoring in NPM1-Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives. International Journal of Molecular Sciences, 2018, 19, 3492.	4.1	52
23	T cell therapy with EBV-specific cytotoxic T-lymphocytes for patients with nasopharyngeal carcinoma. Annals of Oncology, 2018, 29, x11.	1.2	0
24	HHV-6 Infection/Reactivation after Allogeneic Stem Cell Transplantation in Pediatric Patients: Epidemiology, Risk Factors and Outcome. Blood, 2018, 132, 3362-3362.	1.4	0
25	BCR-ABL–specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors. Blood, 2017, 129, 582-586.	1.4	49
26	Detection of Fusarium-specific T cells in hematologic patients with invasive fusariosis. Journal of Infection, 2017, 74, 314-318.	3.3	7
27	Clinical Utility of Epstein-Barr Virus Viral Load Monitoring and Risk Factors for Posttransplant Lymphoproliferative Disorders After Kidney Transplantation: A Single-Center, 10-Year Observational Cohort Study. Transplantation Direct, 2017, 3, e182.	1.6	10
28	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1939-1948.	2.0	19
29	Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncology, The, 2017, 18, 1126-1136.	10.7	58
30	Evidence for CD19B–CD8T cell interactions in blood and tissues from patients with GvHD. Bone Marrow Transplantation, 2017, 52, 459-462.	2.4	1
31	Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss. American Journal of Transplantation, 2017, 17, 692-702.	4.7	23
32	De Novo Donor-Specific HLA Antibodies Developing Early or Late after Transplant Are Associated with the Same Risk of Graft Damage and Loss in Nonsensitized Kidney Recipients. Journal of Immunology Research, 2017, 2017, 1-9.	2.2	19
33	Applications of Haploidentical SCT in Pediatric Patients. Pancreatic Islet Biology, 2017, , 149-178.	0.3	0
34	Acquisition of C3d-Binding Activity by De Novo Donor-Specific HLA Antibodies Correlates With Graft Loss in Nonsensitized Pediatric Kidney Recipients. American Journal of Transplantation, 2016, 16, 2106-2116.	4.7	85
35	Characterization of Immunodominant BK Polyomavirus 9mer Epitope T Cell Responses. American Journal of Transplantation, 2016, 16, 1193-1206.	4.7	40
36	Circulating functional T cells specific to human herpes virus 6 (HHV6) antigens in individuals with chromosomally integrated HHV6. Clinical Microbiology and Infection, 2016, 22, 893-895.	6.0	5

#	Article	IF	CITATIONS
37	Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirusâ€6B reactivation. British Journal of Haematology, 2016, 172, 561-572.	2.5	6
38	The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi. Medical Mycology, 2016, 54, 327-332.	0.7	2
39	Mucorales-Specific T Cells in Patients with Hematologic Malignancies. PLoS ONE, 2016, 11, e0149108.	2.5	40
40	Successful T-cell–depleted Haploidentical Hematopoietic Stem Cell Transplantation in a Child With Dyskeratosis Congenita After a Fludarabine-based Conditioning Regimen. Journal of Pediatric Hematology/Oncology, 2015, 37, 322-326.	0.6	9
41	Posttransplant Soluble B-Cell Activating Factor Kinetics in Pediatric Recipients of First Kidney Allograft. Transplantation, 2015, 99, 243-249.	1.0	9
42	Current preventive strategies and management of Epstein–Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey. Clinical Microbiology and Infection, 2015, 21, 604.e1-604.e9.	6.0	56
43	Serum complement inactivation unveiled prepregnancy donor-specific HLA antibodies leading to postpartum kidney graft loss. Transplant International, 2015, 28, 623-625.	1.6	2
44	Persistent rhinovirus infection in pediatric hematopoietic stem cell transplant recipients with impaired cellular immunity. Journal of Clinical Virology, 2015, 67, 38-42.	3.1	11
45	Identification of transcriptionally active HPV infection in formalin-fixed, paraffin-embedded biopsies of oropharyngeal carcinoma. Human Pathology, 2015, 46, 681-689.	2.0	18
46	Treosulfanâ€based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease. British Journal of Haematology, 2015, 169, 726-736.	2.5	68
47	Markers of squamocolumnar junction cells in normal tonsils and oropharyngeal cancer with and without HPV infection. Histology and Histopathology, 2015, 30, 833-9.	0.7	16
48	DQ Molecules Are The Principal Stimulators of De Novo Donor Specific Antibodies in Non Sensitized Pediatric Kidney Recipients Transplantation, 2014, 98, 62.	1.0	0
49	Longâ€ŧerm molecular remission with persistence of <i><scp>BCR</scp>â€<scp>ABL</scp>1</i> â€specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphiaâ€positive <scp>ALL</scp> . British Journal of Haematology, 2014, 164, 299-302.	2.5	8
50	European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. Clinical Microbiology and Infection, 2014, 20, 74-88.	6.0	112
51	Haploidentical stem cell transplantation in DOCK8 deficiency — Successful control of pre-existing severe viremia with a TCRaß/CD19-depleted graft and antiviral treatment. Clinical Immunology, 2014, 152, 111-114.	3.2	27
52	DQ molecules are the principal stimulators of <i>de novo</i> donor-specific antibodies in nonsensitized pediatric recipients receiving a first kidney transplant. Transplant International, 2014, 27, 667-673.	1.6	53
53	Epstein-Barr virus-related post-transplant lymphoproliferative disorder in solid organ transplant recipients. Clinical Microbiology and Infection, 2014, 20, 109-118.	6.0	105
54	Autologous Human Cytomegalovirus-Specific Cytotoxic T Cells as Rescue Therapy for Ulcerative Enteritis in Primary Immunodeficiency. Journal of Clinical Immunology, 2014, 34, 681-685.	3.8	7

#	Article	IF	CITATIONS
55	Possible alternatives to antimicrobial therapies. Early Human Development, 2014, 90, S16-S18.	1.8	Ο
56	HLA-Haploidentical T Cell–Depleted Allogeneic Hematopoietic Stem Cell Transplantation in Children with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2014, 20, 571-576.	2.0	52
57	Tuberculosis-induced haemophagocytic syndrome in a patient on haemodialysis treated with anti-thymocyte globulin [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2014, 18, 248-249.	1.2	5
58	Intrabone Injection of T-Cell Depleted Peripheral Blood Stem Cells from HLA-Haploidentical Donors to Reduce the Risk of Graft Rejection in Children. Blood, 2014, 124, 1146-1146.	1.4	0
59	Discarded fraction from bone marrow erythrocyte depletion procedure is a good source of multipotent mesenchymal stromal cells. Cytotherapy, 2013, 15, 879-880.	0.7	0
60	Successful treatment of a classic Hodgkin lymphomaâ€ŧype postâ€ŧransplant lymphoproliferative disorder with tailored chemotherapy and Epstein–Barr virusâ€specific cytotoxic T lymphocytes in a pediatric heart transplant recipient. Pediatric Transplantation, 2013, 17, E168-73.	1.0	12
61	Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients. PLoS ONE, 2013, 8, e74326.	2.5	48
62	Immunity to Polyomavirus BK Infection: Immune Monitoring to Regulate the Balance between Risk of BKV Nephropathy and Induction of Alloimmunity. Clinical and Developmental Immunology, 2013, 2013, 1-6.	3.3	49
63	T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results. Annals of Oncology, 2012, 23, 435-441.	1.2	55
64	Reply to "Ethical concerns surrounding the conception of an HLA-compatible child for medical purposes" Haematologica 2012;97(9):e33. Haematologica, 2012, 97, e36-e36.	3.5	0
65	Conceiving a hematopoietic stem cell donor: twenty-five years after our decision to save a child. Haematologica, 2012, 97, 479-481.	3.5	23
66	Posttransplant De Novo Donor-Specific HLA Antibodies Identify Pediatric Kidney Recipients at Risk for Late Antibody-Mediated Rejection. American Journal of Transplantation, 2012, 12, 3355-3362.	4.7	142
67	Is adoptive T-cell therapy for solid tumors coming of age?. Bone Marrow Transplantation, 2012, 47, 1013-1019.	2.4	15
68	Monitoring and managing viral infections in pediatric renal transplant recipients. Pediatric Nephrology, 2012, 27, 705-717.	1.7	33
69	Monitoraggio e gestione delle infezioni virali in riceventi pediatrici di trapianto renale. Giornale De Techniche Nefrologiche & Dialitiche, 2011, 23, 38-44.	0.1	Ο
70	Immunotherapeutic Intervention against Sarcomas. Journal of Cancer, 2011, 2, 350-356.	2.5	6
71	T Cell Therapy for Nasopharyngeal Carcinoma. Journal of Cancer, 2011, 2, 341-346.	2.5	26
72	BCR–ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy. Blood Cancer Journal, 2011, 1, e30-e30.	6.2	8

#	Article	IF	CITATIONS
73	Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplantation, 2011, 46, 987-992.	2.4	106
74	Emergence of BCR-ABL–specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment. Blood, 2010, 115, 1512-1518.	1.4	45
75	The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica, 2010, 95, 1769-1777.	3.5	89
76	Successful medical treatment of EBV smooth muscle tumor in a renal transplant recipient. Pediatric Transplantation, 2010, 14, E101-E104.	1.0	17
77	Biological individuality and the new frontiers of immunological tolerance in hematopoietic stem cell transplantation. Haematologica, 2010, 95, 1447-1451.	3.5	0
78	Gene therapy of haemoglobinopathy: An Italy-USA project. Pharmaceuticals Policy and Law, 2010, 12, 151-155.	0.1	0
79	Immunotherapy against EBV-lymphoma in recipients of HSCT. Expert Review of Hematology, 2010, 3, 625-632.	2.2	6
80	Cell-based therapies: careful safety assessment for minimization of risk. Cytotherapy, 2010, 12, 710-712.	0.7	1
81	Clinical, virological and immunological aspects of adoptive cell therapy against EBV-related diseases. Microbiologia Medica, 2009, 24, .	0.1	0
82	Antibody Responses to Recombinant Polyomavirus BK Large T and VP1 Proteins in Young Kidney Transplant Patients. Journal of Clinical Microbiology, 2009, 47, 2577-2585.	3.9	53
83	Unrelated hematopoietic stem cell transplantation for Cernunnosâ€XLF deficiency. Pediatric Transplantation, 2009, 13, 785-789.	1.0	30
84	Arming CTLs against immunosuppressors. Blood, 2009, 114, 4759-4760.	1.4	1
85	Treosulfanâ€based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. British Journal of Haematology, 2008, 143, 548-551.	2.5	60
86	Expression of p75 chain of IL-2 receptor in the early immunological reconstitution after allogeneic bone marrow transplantation. Clinical and Experimental Immunology, 2008, 97, 510-516.	2.6	7
87	Polyomavirus BK Replication Dynamics In Vivo and In Silico to Predict Cytopathology and Viral Clearance in Kidney Transplants. American Journal of Transplantation, 2008, 8, 2368-2377.	4.7	94
88	T cell therapy of Epstein–Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells, Molecules, and Diseases, 2008, 40, 68-70.	1.4	41
89	Kinetics of Epstein-Barr Virus DNA Load in Different Blood Compartments of Pediatric Recipients of T-Cell-Depleted HLA-Haploidentical Stem Cell Transplantation. Journal of Clinical Microbiology, 2008, 46, 3672-3677.	3.9	47
90	T-cell Lines Specific for Peptides of Adenovirus Hexon Protein and Devoid of Alloreactivity Against Recipient Cells can be Obtained From HLA-haploidentical Donors. Journal of Immunotherapy, 2008, 31, 529-536.	2.4	43

#	Article	lF	CITATIONS
91	Cellular immune responses to BK virus. Current Opinion in Organ Transplantation, 2008, 13, 569-574.	1.6	73
92	Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrology Dialysis Transplantation, 2007, 23, 1196-1202.	0.7	142
93	Major changes in trophic dynamics in large, deep sub-alpine Lake Maggiore from 1940s to 2002: a high resolution comparative palaeo-neolimnological study. Freshwater Biology, 2007, 52, 2256-2269.	2.4	83
94	Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patientâ€specific tumour idiotype protein or idiotype (VDJ)â€derived class lâ€restricted peptides. British Journal of Haematology, 2007, 139, 415-424.	2.5	58
95	Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation. American Journal of Transplantation, 2007, 7, 1648-1655.	4.7	192
96	Prospective Monitoring of Polyomavirus BK Replication and Impact of Pre-Emptive Intervention in Pediatric Kidney Recipients. American Journal of Transplantation, 2007, 7, 2727-2735.	4.7	215
97	Transplantation of T-Cell Depleted Peripheral Blood Haematopoietic Stem Cells from an HLA-Disparate Family Donor for Children with Hematological Malignancies Blood, 2007, 110, 3071-3071.	1.4	5
98	Adenovirus Specific T-Cell Lines Devoid of Alloreactivity Against Haploidentical Recipients Can Be Obtained Using a Set of Adenovirus Hexon Peptides Blood, 2007, 110, 3273-3273.	1.4	0
99	BK virus regulatory region sequence deletions in a case of human polyomavirus associated nephropathy (PVAN) after kidney transplantation. Journal of Clinical Virology, 2006, 35, 106-108.	3.1	8
100	Specific autologous cytotoxic T lymphocytes for chronic varicella in a liver transplanted child. Pediatric Transplantation, 2006, 10, 240-243.	1.0	11
101	Polyomavirus-associated nephropathy: update on BK virus-specific immunity. Transplant Infectious Disease, 2006, 8, 86-94.	1.7	113
102	Successful In Vitro Priming of EBV-Specific CD8+ T Cells Endowed with Strong Cytotoxic Function from T Cells of EBV-Seronegative Children. American Journal of Transplantation, 2006, 6, 2169-2176.	4.7	24
103	Treatment of Epstein–Barr Virus Infections: Chemotherapy, Antiviral Therapy, and Immunotherapy. Infectious Disease and Therapy, 2006, , 353-374.	0.0	3
104	Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells. American Journal of Transplantation, 2005, 5, 1415-1422.	4.7	108
105	Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes. Journal of Clinical Oncology, 2005, 23, 8942-8949.	1.6	265
106	Human Mesenchymal Stem Cells and Cyclosporin A Exert a Synergistic Suppressive Effect on In Vitro Activation of Alloantigen-Specific Cytotoxic Lymphocytes. Biology of Blood and Marrow Transplantation, 2005, 11, 1031-1032.	2.0	51
107	Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica, 2005, 90, 516-25.	3.5	444
108	Adoptive transfer of allogeneic Epstein–Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boostsLMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Annals of Oncology, 2004, 15, 113-117.	1.2	79

#	Article	IF	CITATIONS
109	Reconstructing long-term changes in Daphnia's body size from subfossil remains in sediments of a small lake in the Himalayas. Journal of Paleolimnology, 2004, 32, 95-107.	1.6	26
110	Polyomavirus BK-Specific Immunity after Kidney Transplantation. Transplantation, 2004, 78, 1229-1232.	1.0	108
111	Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation. Best Practice and Research in Clinical Haematology, 2004, 17, 479-492.	1.7	8
112	T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. Blood, 2004, 103, 4322-4329.	1.4	36
113	Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation. Best Practice and Research in Clinical Haematology, 2004, 17, 479-492.	1.7	6
114	Retransplantation after kidney graft loss due to polyoma BK virus nephropathy: successful outcome without original allograft nephrectomy. American Journal of Kidney Diseases, 2003, 42, 821-825.	1.9	51
115	Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors. Experimental Hematology, 2003, 31, 1031-1038.	0.4	24
116	Successful T-cell-depleted, related haploidentical peripheral blood stem cell transplantation in a patient with Fanconi anaemia using a fludarabine-based preparative regimen without radiation. Bone Marrow Transplantation, 2003, 31, 437-440.	2.4	20
117	Dendritic Cells Pulsed with Polyomavirus BK Antigen Induce Ex Vivo Polyoma BK Virus–Specific Cytotoxic T-Cell Lines in Seropositive Healthy Individuals and Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2003, 14, 3197-3204.	6.1	73
118	Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation, 2003, 75, 1266-1270.	1.0	168
119	Cellular immunotherapy for viral infections in solid organ transplant recipients. Current Opinion in Organ Transplantation, 2002, 7, 314-319.	1.6	8
120	Infusion of autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood, 2002, 99, 2592-2598.	1.4	230
121	Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica, 2002, 87, 67-77.	3.5	61
122	Correction of DiGeorge Anomaly with EBV-Induced Lymphoma by Transplantation of Organ-Cultured Thymus and Epstein–Barr-Specific Cytotoxic T Lymphocytes. Clinical Immunology, 2001, 98, 54-61.	3.2	20
123	Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood, 2001, 98, 3359-3366.	1.4	55
124	Human alloantigen-specific anergic cells induced by a combination of CTLA4-lg and CsA maintain anti-leukemia and anti-viral cytotoxic responses. Bone Marrow Transplantation, 2001, 27, 1263-1273.	2.4	14
125	Analysis of immune reconstitution in children undergoing cord blood transplantation. Experimental Hematology, 2001, 29, 371-379.	0.4	119
126	Ex-vivo expansion after gene marking of hematopoietic stem cells from cord blood under serum free conditions. Experimental Hematology, 2000, 28, 74.	0.4	0

#	Article	IF	CITATIONS
127	Title is missing!. Journal of Paleolimnology, 2000, 23, 117-127.	1.6	24
128	The decline of Daphnia hyalina galeata in Lago Maggiore: a comparison of the population dynamics before and after oligotrophication. Aquatic Sciences, 2000, 62, 142-153.	1.5	15
129	Biomass estimates of freshwater zooplankton from length-carbon regression equations. Journal of Limnology, 2000, 59, 15.	1.1	63
130	The decline of. Aquatic Sciences, 2000, 62, 142.	1.5	14
131	High Levels of Epstein-Barr Virus DNA in Blood of Solid-Organ Transplant Recipients and Their Value in Predicting Posttransplant Lymphoproliferative Disorders. Journal of Clinical Microbiology, 2000, 38, 613-619.	3.9	156
132	Studies on zooplankton of Lago Paione Superiore. Journal of Limnology, 1999, 58, 131.	1.1	31
133	An unusual type of Daphnia head shields from plankton and sediments of Himalayan lakes Journal of Limnology, 1999, 58, 29.	1.1	6
134	Depletion of Alloreactive T Cells by a Specific Anti–Interleukin-2 Receptor p55 Chain Immunotoxin Does Not Impair In Vitro Antileukemia and Antiviral Activity. Blood, 1999, 93, 3550-3557.	1.4	119
135	Characterisation of CTL directed towards non-inherited maternal alloantigens in human cord blood. Bone Marrow Transplantation, 1999, 24, 1161-1166.	2.4	35
136	Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls. Journal of Clinical Immunology, 1998, 18, 193-201.	3.8	21
137	Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study. Bone Marrow Transplantation, 1998, 22, 743-750.	2.4	17
138	Organisms' response in a chronically polluted lake supports hypothesized link between stress and size. Limnology and Oceanography, 1998, 43, 1938-1943.	3.1	65
139	Length-specific carbon content of theDaphnia population in a large subalpine lake, Lago Maggiore (Northern Italy): The importance of seasonality. Aquatic Sciences, 1997, 59, 48-56.	1.5	6
140	A late glacial and holocene record of biological and environmental changes from the crater Lake Albano, Central Italy: An interdisciplinary european project (PALICLAS). Water, Air, and Soil Pollution, 1997, 99, 601-613.	2.4	12
141	High frequency of Epstein-Barr virus (EBV) lymphoblastoid cell line-reactive lymphocytes in cord blood: evaluation of cytolytic activity and IL-2 production. Clinical and Experimental Immunology, 1997, 107, 312-320.	2.6	29
142	Infusion of donor-derived peripheral blood leukocytes after transplantation of cord blood progenitor cells can increase the graft-versus-leukaemia effect. Leukemia, 1997, 11, 729-731.	7.2	9
143	Transplantation of cord blood progenitor cells can promote bone resorption in autosomal recessive osteopetrosis. Bone Marrow Transplantation, 1997, 20, 701-705.	2.4	14
144	Length-specific carbon content of the Daphnia population in a large subalpine lake, Lago Maggiore (Northern Italy): The importance of seasonality. Aquatic Sciences, 1997, 59, 48-56.	1.5	1

#	Article	IF	CITATIONS
145	Role of allogeneic bone marrow transplantation from an HLA-identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia. British Journal of Haematology, 1996, 92, 49-54.	2.5	24
146	Frequency of donor cytotoxic T cell precursors does not correlate with occurrence of acute graft-versus-host disease in children transplanted using unrelated donors. Journal of Clinical Immunology, 1996, 16, 107-114.	3.8	11
147	Measuring gene–transfer efficiency. Nature Medicine, 1996, 2, 1280-1281.	30.7	14
148	Restricted TCR repertoire and long-term persistence of donor-derived antigen-experienced CD4+ T cells in allogeneic bone marrow transplantation recipients. Journal of Immunology, 1996, 157, 5739-47.	0.8	42
149	Hematopoietic and immune recovery after transplantation of cord blood progenitor cells in children. Bone Marrow Transplantation, 1996, 18, 1095-101.	2.4	49
150	Seasonal changes in size of the feeding basket of Leptodora kindtii (Focke) in Lago Maggiore as related to variations in prey size selection. Limnology and Oceanography, 1995, 40, 834-838.	3.1	25
151	Quantitation of human cytomegalovirus DNA in bone marrow transplant recipients. British Journal of Haematology, 1995, 91, 674-683.	2.5	65
152	Juvenile chronic myelogenous leukemia: In vitro characterization before and after allogeneic bone marrow transplantation. Medical and Pediatric Oncology, 1995, 24, 166-170.	1.0	2
153	Antibody response to pneumococcal vaccine in children receiving bone marrow transplantation. Journal of Clinical Immunology, 1995, 15, 137-144.	3.8	75
154	Temporal variations of fossil Cladocera in the sediments of Lake Orta (N. Italy) over the last 400 years. Journal of Paleolimnology, 1995, 14, 113-122.	1.6	39
155	Herpes simplex virus-specific human cytotoxic T-cell colonies expressing either gamma delta or alpha beta T-cell receptor: role of accessory molecules on HLA-unrestricted killing of virus-infected targets. Immunology, 1995, 85, 49-56.	4.4	18
156	Alloantigen-induced human lymphocytes rendered nonresponsive by a combination of anti-CD80 monoclonal antibodies and cyclosporin-A suppress mixed lymphocyte reaction in vitro. Journal of Immunology, 1995, 155, 5506-11.	0.8	17
157	Human cytomegalovirus (HCMV) infection in paediatric patients given allogeneic bone allogeneic bone marrow transplantation: role of early antiviral treatment for HCMV antigenaemaia on Patients' outcome. British Journal of Haematology, 1994, 88, 64-71.	2.5	71
158	Variations in carbon and nitrogen content with body length of Daphnia hyalina-galeata s.l. from laboratory and field observations. Journal of Plankton Research, 1994, 16, 1303-1314.	1.8	17
159	Herpes Simplex Virus-1-Specific Human Cytotoxic T Lymphocytes Are Induced <i>in Vitro</i> by Autologous Virus-Infected Mononuclear Cells. Viral Immunology, 1992, 5, 93-103.	1.3	5